Text Size

The Effects of Broccoli Sprout Extract on Obstructive Lung Disease

This study is currently recruiting participants.
Verified September 2012 by Johns Hopkins University
Sponsor:
Information provided by (Responsible Party):
Robert Brown, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00994604
First received: October 13, 2009
Last updated: September 11, 2012
Last verified: September 2012
History of Changes
  Purpose

The purpose of this study is to examine whether broccoli sprout extract can effect lung function measurements in individuals with asthma and COPD.


Condition Intervention
Asthma
COPD
 Drug: broccoli sprout extract

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • The primary outcome is the change in bronchodilation and bronchoprotection after broccoli sprout extract [ Time Frame: end of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in biomarkers, Change in inflammatory mediators, Change in airway distensibility, Change in parenchyma [ Time Frame: end of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: October 2009
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: broccoli sprout extract Drug: broccoli sprout extract
consumption of broccoli sprout extract for 2 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • asthma
  • COPD

Exclusion Criteria:

  • currently on chronic oral steroid medications
  • current respiratory symptoms
  • pregnant
  • FEV1 less than 40% predicted at baseline
  • extreme degrees of bronchial hyperreactivity
  • recent respiratory infection (<3 weeks)
  • unstable symptoms in the prior month
  • a history of intubation for respiratory symptoms within the past year
  • any history of cardiac disease.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00994604

Contacts
Contact: Curt Reynolds 410-299-2429

Locations
United States, Maryland
Johns Hopkins Medical Institutions Recruiting
Baltimore, Maryland, United States, 21205
Contact: Curt Reynolds     410-299-2429        
Principal Investigator: Robert H Brown, M.D., M.P.H.            
Sponsors and Collaborators
Johns Hopkins University
  More Information

No publications provided

Responsible Party: Robert Brown, Professor, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00994604     History of Changes
Other Study ID Numbers: RB-001
Study First Received: October 13, 2009
Last Updated: September 11, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Lung Diseases, Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013